Stock of the Week

Before you go, we thought you'd like these...
Before you go close icon

The following video is part of our "Motley Fool Conversations" series, in which advisor Charly Travers and analyst Jason Moser discuss topics across the investing world.

Gilead Sciences is a world-class drug company that has created tremendous value for shareholders with a stock that's up five times over the past decade. The company, best known for its work in HIV drug development, is trying to branch out in another important anti-viral market, the treatment of hepatitis C. Gilead's recent clinical trial data on HCV drug GS-7977 was poorly received, sending the stock down 20%. Is now the time to buy?

Every now and again, we come across a stock that has us so excited we can hardly contain our investing enthusiasm. We've uncovered one such pick with so much promise that we've dubbed it "The Motley Fool's Top Stock for 2012." We've created a special free report for investors to uncover this soon-to-be rock star. The report highlights a company that is revolutionizing commerce in Latin America, and you can get instant access to the name of this company by clicking here to download it now.

At the time this article was published Charly Travers and Jason Moser have no positions in the stocks mentioned above. The Motley Fool owns shares of Gilead Sciences.Motley Fool newsletter services recommendGilead Sciences and Vertex Pharmaceuticals. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners